Busulfan 60mg/10ml solution for infusion vials
Requires a prescription from a doctor or prescriber
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Busulfan
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
3 branded products available
MHRA licensed products
View all licensed products for Busulfan on the MHRA register
Busulfan 60mg/10ml concentrate for solution for infusion vials
Busulfan 60mg/10ml concentrate for solution for infusion vials
Busulfan 60mg/10ml concentrate for solution for infusion vials
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(5)
Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant (TA640)
Ruxolitinib for treating polycythaemia vera (TA921)
Non-Hodgkin lymphoma: diagnosis and management (NG52)
Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over (TA1003)
Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over (TA1044)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 9 · Randomised trials: 13 · 1983–2026
Showing the 50 most relevant studies, sorted by most relevant.
Ruth Ladenstein, Ulrike Pötschger, Andrew D.J. Pearson, et al.
The Lancet Oncology, 2017
- Antineoplastic Combined Chemotherapy Protocols
- Bone Neoplasms
- Busulfan
Olle Ringdén, Tapani Ruutu, Mats Remberger, et al.
Blood, 1994
- Whole-Body Irradiation
- Bone Marrow Transplantation
- Busulfan
Didier Blaise, D Maraninchi, E Archimbaud, et al.
Blood, 1992
- Actuarial Analysis
- Antineoplastic Combined Chemotherapy Protocols
- Busulfan
Olle Ringdén, Mats Remberger, Tapani Ruutu, et al.
Blood, 1999
- Alopecia
- Bronchiolitis Obliterans
- Busulfan
Nancy Bunin, Richard Aplenc, Naynesh Kamani, et al.
Bone Marrow Transplantation, 2003
- Whole-Body Irradiation
- Busulfan
- Recurrence
Kazunori Ohnishi, R Ohno, Masao Tomonaga, et al.
Blood, 1995
- Blood Cell Count
- Bone Marrow
- Busulfan
Alessandro Rambaldi, Anna Grassi, Arianna Masciulli, et al.
The Lancet Oncology, 2015
- Hematopoietic Stem Cell Transplantation
- Transplantation Conditioning
- Antineoplastic Agents
D. Beelen, R. Trenschel, M. Stelljes, et al.
The Lancet. Haematology, 2020
Maqbool S, Khan I, Ibrahim M, et al.
2026
- Multiple Myeloma
- Busulfan
- Melphalan
Shimada T, Masaki T, Koyamada R, et al.
2026
- Hematologic Neoplasms
- Busulfan
- Cyclophosphamide
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
2.6 hours
Mechanism
Busulfan is an alkylating agent that contains 2 labile methanesulfonate groups a…
Food interactions
4 warnings
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
2 mg
Half-life
2.6 hours
Protein binding
32%
Metabolism
Elimination
30%
Clearance
2.52 ml/min/kg
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 911 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
In children (1.5 - 6 years old), the absolute bioavailability was 68% ± 31%. When a single oral dose is given to patients, the area under the curve (AUC) was 130 ng•hr/mL. The peak plasma concentration when given orally is 30 ng/mL (after dose normalization to 2 mg).
It takes 0.9 hours to reach peak plasma concentration after dose normalization to 4 mg.
Other GST isoforms that are also involved are GSTM1 and GSTP1. At least 12 metabolites have been identified among which tetrahydrothiophene, tetrahydrothiophene 12-oxide, sulfolane, and 3-hydroxysulfolane were identified. These metabolites do not have cytotoxic activity.
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC L01AB01
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Busulfan
Additional database identifiers
Drugs Product Database (DPD)
9556
ChemSpider
2384
BindingDB
50237623
ZINC
ZINC000001530572
HUGO Gene Nomenclature Committee (HGNC)
HGNC:4632
GenAtlas
GSTM1
GeneCards
GSTM1
GenBank Gene Database
X08020
GenBank Protein Database
31924
UniProt Accession
GSTM1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:4638
GenAtlas
GSTP1
GeneCards
GSTP1
GenBank Gene Database
M24485
GenBank Protein Database
31946
UniProt Accession
GSTP1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:7063
GenAtlas
MGST2
GeneCards
MGST2
GenBank Gene Database
U77604
GenBank Protein Database
1747521
UniProt Accession
MGST2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2637
GenAtlas
CYP3A4
GeneCards
CYP3A4
GenBank Gene Database
M18907
Guide to Pharmacology
1337
UniProt Accession
CP3A4_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:4627
GenAtlas
GSTA2
GeneCards
GSTA2
GenBank Gene Database
M16594
GenBank Protein Database
306811
UniProt Accession
GSTA2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:4626
GenAtlas
GSTA1
GeneCards
GSTA1
GenBank Gene Database
M15872
GenBank Protein Database
306809
UniProt Accession
GSTA1_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q348922), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.